Integra LifeSciences Holdings C (IART) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Integra LifeSciences Holdings C

NasdaqGS•Healthcare•Medical Devices

$16.72+0.28(0.02%)Market closed

Market Cap

$1.20B

P/S

0.7x

P/B

1.1x

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Surgical and Tissue Technologies segments. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. It also offers after-market services; surgical headlamps and instrumentation; instrument patterns and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices. In addition, the company provides treatment of acute wounds, such as burns; chronic wounds, including diabetic foot ulcers; and surgical tissue repair applications, including hernia reinforcement, tendon protection, and peripheral nerve repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, and nerve and tendon repair products. Additionally, the company is involved in the ear, nose, and throat business that includes instrumentation, balloon technologies for sinus dilation and eustachian tube dilation, and surgical navigation systems. It offers its products directly through various salesforces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, the Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was formerly known as Integra LifeSciences Corp. and changed its name to Integra LifeSciences Holdings Corporation in June 1995. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.

How this company scores

WeakMetricSide Score: 62/100

Grade capped at D — Interest coverage below 1× (0.8x) — earnings cannot cover interest. Strongest: Cash & Earnings Quality (18/25); weakest: Balance Sheet & Red Flags (11/25).

Profitability17/25

Growth16/25

Balance Sheet & Red Flags11/25

Cash & Earnings Quality18/25

Strengths

Long cash runwayCash-backed earningsProfit converts from growthConsistent growth

Grade capped at D

Interest coverage below 1× (0.8x) — earnings cannot cover interest.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 95.4x5y range 20.9x – 95.4x

Currently above its 12-quarter median.

P/S · 0.7x5y range 0.4x – 3.9x

Currently below its 20-quarter median.

P/B · 1.1x5y range 0.7x – 3.7x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 5 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $1.20B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $1.65B
Q. Revenue: $418.76M
TTM EBITDA: $295.29M
TTM Op. Income: $65.56M
Q. Op. Income: $19.29M
TTM Net Income: $-7.24M
Q. Net Income: $4.48M
EPS: $0.06
Shares Out.: $77.29M

$1.65B in TTM revenue grew 1.6% YoY, reaching $418.76M last quarter. TTM EBITDA of $295.29M and TTM operating income of $65.56M show growth is flowing through to the bottom line. However, net income is negative at $7.24M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has risen for 2 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 52.5%
EBITDA Margin: 13.7%
Op. Margin: 4.6%
Net Margin: 1.1%

Op. margin of 4.6% is up 128.0% YoY — cost efficiency is improving. Net margin at 1.1% and gross margin of 52.5% show how much of each revenue dollar survives to profit. Over the past year, operating margin is up 104% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 0.7x
P/B Ratio: 1.1x

P/S of 0.7x and P/B of 1.1x. P/S is low relative to typical market levels.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $3.56B
Cash: $214.41M
Long-Term Debt: $707.19M
Book Value: $1.04B
D/E Ratio: 0.7
Debt/EBITDA: 12.3

With $3.56B in assets and $707.19M in long-term debt, D/E is 0.7and book value is $1.04B — a conservative capital structure with a cushion to weather downturns. Across the last 8 quarters, debt/equity has fallen for 4 consecutive quarters — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $22.80M
TTM Free Cash Flow: $25.80M
FCF Margin: 1.6%
FCF / Net Income: -3.6

TTM FCF of $25.80M on $22.80M in operating cash flow. The FCF / Net Income ratio of -3.6x means the business consumes cash — it is not yet self-funding. Across the last 8 quarters, free cash flow has risen for 2 consecutive quarters — an improving trend.